Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma
Authors:
Open Access
- 25 June 2014
- journal article
- case report
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (9) , 872-875
Abstract
We herein report a case of fatal fulminant hepatitis secondary to crizotinib administration. The patient was 54-year-old female with a history of Hepatitis C infection (not current), dermatomyositis and steroid-induced diabetes mellitus. She was diagnosed with advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement. We began 400 mg of crizotinib as first-line therapy. No adverse effects were seen until Day 16. On Day 29, she was admitted to hospital with elevated liver enzymes (aspartate aminotransferase 3236 IU/l, alanine aminotransferase 5201 IU/l) and coagulopathy (prothrombin time <10%), and was diagnosed with crizotinib-induced fulminant hepatitis. We started intensive care, using plasma exchange, continuous hemodiafiltration and high-dose steroid therapy. Unfortunately, she did not respond to therapies, and died on Day 36. The mechanism and risk factors of crizotinib-induced hepatotoxicity are uncertain. Physicians should be aware of possible adverse effects of crizotinib. A systemic survey is imperative to identify possible risk factors of crizotinib-related hepatotoxicity.Keywords
This publication has 16 references indexed in Scilit:
- Understanding, recognizing, and managing toxicities of targeted anticancer therapiesCA: A Cancer Journal for Clinicians, 2013
- Elephantiasis NeuromatosaNew England Journal of Medicine, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyThe Lancet Oncology, 2012
- Acute liver failure in Japan: definition, classification, and prediction of the outcomeJournal of Gastroenterology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Standardization of nomenclature and causality assessment in drug‐induced liver injuryHepatology, 2010
- Development and validation of a clinical scale for the diagnosis of drug-induced hepatitisHepatology, 1997
- Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuriesJournal of Clinical Epidemiology, 1993
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975